Venous Thromboembolism Prevention in Cancer Outpatients
Venous thromboembolism (VTE) has serious consequences for patients with cancer, including mortality. VTE is preventable with appropriate thromboprophylaxis, but prior public health efforts have focused on prophylaxis in the inpatient setting. However, most VTE events in malignancy currently occur in outpatients. Several recent clinical trials have addressed thromboprophylaxis in the ambulatory setting. Their findings suggest potential benefit, but with significant variation in underlying risk. A risk-adapted approach that incorporates risk of thrombosis, risk of bleeding, and patient preference can target high-risk patients and also allow low-risk patients to avoid prophylaxis. Risk assessment is therefore key to patient selection for outpatient prophylaxis. This article focuses on results of recent trials and updates from major guideline panels, with the intent of providing guidance to clinical providers.
This activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Describe the rationale for a risk-adapted approach to the prophylaxis of venous thromboembolism (VTE) in cancer patients
- Summarize the guidelines on cancer-associated thrombosis as it pertains to outpatient settings
- Identify three recommendations for clinician interactions with cancer patients in an outpatient setting
Alok A. Khorana, MD
Taussig Cancer Institute
Cleveland Clinic Foundation
- 1.00 Participation
- 1.00 Nurse
- 1.00 Physician